The evolution of SARS-CoV-2 with increasing changes in the functional domains of the S protein is usually considered capable of affecting diagnostic tests and COVID-19 treatment (e.g., with hyperimmune plasma from COVID-19 convalescent patients). This evidence concerns the gene PROS1 and COVID-19.